Covered recipient · General Payments record
BRIAN CONFREY MAZZARELLA
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$394,196.79
269 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $347,686.28 | 71 |
| Travel and Lodging | $19,587.72 | 39 |
| Consulting Fee | $13,000.00 | 6 |
| Food and Beverage | $9,922.79 | 151 |
| Honoraria | $4,000.00 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| NeoTract Inc. | $393,958.80 | 259 |
| Boston Scientific Corporation | $80.47 | 3 |
| PROCEPT BioRobotics Corporation | $80.27 | 3 |
| 180 Medical, Inc. | $22.34 | 1 |
| Allergan Inc. | $20.89 | 1 |
| Endo Pharmaceuticals Inc. | $18.86 | 1 |
| PFIZER INC. | $15.16 | 1 |
Page 5 of 6; records 201–250 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRIAN CONFREY MAZZARELLA
NPI 1417265851 · CMS profile ID 1390616
Allopathic & Osteopathic Physicians / Urology
LAKEWAY, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 6; records 201–250 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1417265851?year=2019&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRIAN CONFREY MAZZARELLA, NPI 1417265851, CMS profile ID 1390616. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417265851?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). BRIAN CONFREY MAZZARELLA, NPI 1417265851, CMS profile ID 1390616. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417265851?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- BRIAN CONFREY MAZZARELLA, NPI 1417265851, CMS profile ID 1390616, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1417265851?year=2019&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
269 matching records · $394,196.79 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–250 of 269.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| NeoTract Inc. | $67.00 | 04/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688528041 | CMS |
| NeoTract Inc. | $69.00 | 04/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688528075 | CMS |
| NeoTract Inc. | $421.51 | 04/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688528039 | CMS |
| NeoTract Inc. | $16.24 | 04/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688550573 | CMS |
| NeoTract Inc. | $103.74 | 04/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688550575 | CMS |
| NeoTract Inc. | $635.96 | 04/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688528073 | CMS |
| NeoTract Inc. | $6,600.00 | 04/10/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543185 | CMS |
| NeoTract Inc. | $15,000.00 | 04/10/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543187 | CMS |
| NeoTract Inc. | $3,300.00 | 04/10/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543189 | CMS |
| NeoTract Inc. | $45.43 | 04/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543191 | CMS |
| NeoTract Inc. | $273.27 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543193 | CMS |
| NeoTract Inc. | $26.99 | 04/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543195 | CMS |
| NeoTract Inc. | $136.35 | 04/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688550545 | CMS |
| NeoTract Inc. | $43.87 | 03/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688550569 | CMS |
| NeoTract Inc. | $2,500.00 | 03/27/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543179 | CMS |
| NeoTract Inc. | $1,500.00 | 03/27/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543181 | CMS |
| NeoTract Inc. | $1,400.00 | 03/27/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543183 | CMS |
| NeoTract Inc. | $12.79 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688550541 | CMS |
| NeoTract Inc. | $102.27 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688550571 | CMS |
| PROCEPT BioRobotics Corporation | $22.18 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705883743 | CMS |
| NeoTract Inc. | $3,800.00 | 03/14/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543177 | CMS |
| NeoTract Inc. | $3.37 | 03/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688527947 | CMS |
| NeoTract Inc. | $116.96 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688550533 | CMS |
| NeoTract Inc. | $34.45 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688550535 | CMS |
| NeoTract Inc. | $22.88 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688550539 | CMS |
| NeoTract Inc. | $133.00 | 03/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543373 | CMS |
| NeoTract Inc. | $24.84 | 03/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688527985 | CMS |
| NeoTract Inc. | $494.94 | 03/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543365 | CMS |
| NeoTract Inc. | $196.12 | 03/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543371 | CMS |
| Endo Pharmaceuticals Inc. | $18.86 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685071199 | CMS |
| NeoTract Inc. | $22.91 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688528195 | CMS |
| NeoTract Inc. | $127.44 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543367 | CMS |
| NeoTract Inc. | $43.41 | 03/07/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543369 | CMS |
| NeoTract Inc. | $243.65 | 03/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688546349 | CMS |
| NeoTract Inc. | $118.54 | 03/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688528213 | CMS |
| NeoTract Inc. | $47.57 | 03/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688545921 | CMS |
| NeoTract Inc. | $9.85 | 03/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688545943 | CMS |
| NeoTract Inc. | $8,400.00 | 02/27/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543173 | CMS |
| NeoTract Inc. | $550.51 | 02/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543175 | CMS |
| NeoTract Inc. | $242.52 | 02/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688546523 | CMS |
| NeoTract Inc. | $288.30 | 02/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688546527 | CMS |
| NeoTract Inc. | $423.76 | 02/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688548567 | CMS |
| NeoTract Inc. | $12,600.00 | 02/14/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543169 | CMS |
| NeoTract Inc. | $600.00 | 02/14/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688543171 | CMS |
| NeoTract Inc. | $144.95 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688527949 | CMS |
| NeoTract Inc. | $31.58 | 02/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688548207 | CMS |
| NeoTract Inc. | $127.80 | 02/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688548443 | CMS |
| NeoTract Inc. | $31.58 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688548205 | CMS |
| NeoTract Inc. | $11.64 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688547921 | CMS |
| NeoTract Inc. | $29.44 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688548185 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,368,064.91 | 131 |
| PY2024 | Principal investigator | $1,334,006.10 | 79 |
| PY2023 | Principal investigator | $50,424.52 | 18 |
| PY2022 | Principal investigator | $114,657.35 | 20 |
| PY2021 | Principal investigator | $307,941.17 | 17 |
| PY2020 | Principal investigator | $24,628.88 | 1 |
| PY2019 | Principal investigator | $80,124.32 | 4 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
131 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $35,000.00 | 12/31/2025 | Non-covered Recipient Entity Urology Austin | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | No dispute reported | 06/30/2026 | 1235992285 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,538.00 | 12/29/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175335081 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,727.00 | 12/29/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175335103 |
| Principal investigator 1 | Janssen Research & Development, LLC | $48,091.00 | 12/29/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175335112 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21.00 | 12/26/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175334858 |
| Principal investigator 1 | Janssen Research & Development, LLC | $828.00 | 12/26/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175335145 |
| Principal investigator 1 | Janssen Research & Development, LLC | $990.00 | 12/26/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175335306 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,808.00 | 12/25/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175334730 |
| Principal investigator 1 | Janssen Research & Development, LLC | $621.00 | 12/25/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175334818 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,989.70 | 12/23/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco | No dispute reported | 06/30/2026 | 1185539481 |
| Principal investigator 1 | Janssen Research & Development, LLC | $73,865.00 | 12/23/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) | No dispute reported | 06/30/2026 | 1175334781 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,779.00 | 12/22/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175334827 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,558.00 | 12/18/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175334977 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,202.00 | 12/15/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175335007 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,275.00 | 12/15/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175335056 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,114.00 | 11/24/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175277310 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,200.00 | 11/24/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175335000 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,499.00 | 11/07/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175335249 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 11/07/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175335298 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43,627.60 | 11/05/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176655016 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,593.00 | 11/03/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175334971 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,559.00 | 10/30/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175334738 |
| Principal investigator 1 | Janssen Research & Development, LLC | $800.00 | 10/23/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175335217 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 10/13/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175334907 |
| Principal investigator 1 | Janssen Research & Development, LLC | $133.00 | 10/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175334798 |
| Principal investigator 1 | Janssen Research & Development, LLC | $800.00 | 10/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175335161 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,372.00 | 10/03/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175335212 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,444.00 | 10/02/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175277317 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,319.00 | 10/02/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175335095 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,500.00 | 09/29/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175335271 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,959.00 | 09/17/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175276899 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $211.29 | 09/15/2025 | Non-covered Recipient Entity UROLOGY AUSTIN LAKEWAY | A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment | No dispute reported | 06/30/2026 | 1190304561 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,244.00 | 09/08/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175335187 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,739.00 | 09/08/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175335204 |
| Principal investigator 1 | Arrow International, Inc. | $1,841.50 | 08/29/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470441 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,722.00 | 08/28/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175277496 |
| Principal investigator 1 | Janssen Research & Development, LLC | $600.00 | 08/28/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175334888 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,255.00 | 08/11/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175334882 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,677.40 | 08/01/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641703 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,501.00 | 07/31/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175334849 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,444.00 | 07/28/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175275415 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,957.00 | 07/28/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175334765 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,168.00 | 07/28/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175334942 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,905.00 | 07/28/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175335257 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,518.00 | 07/21/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175334991 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,897.00 | 07/18/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175334949 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,393.00 | 07/17/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175275718 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,494.00 | 07/14/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175335130 |
| Principal investigator 1 | Arrow International, Inc. | $1,050.00 | 07/11/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470413 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,225.80 | 07/09/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176640296 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29,602.00 | 07/07/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175335066 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,050.00 | 07/04/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175334771 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,246.00 | 07/04/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175335122 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35,526.00 | 06/30/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175334897 |
| Principal investigator 1 | Arrow International, Inc. | $4,902.20 | 06/27/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470409 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,957.00 | 06/27/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175334756 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,413.00 | 06/25/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175275213 |
| Principal investigator 1 | Janssen Research & Development, LLC | $87.00 | 06/11/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175277038 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,135.00 | 06/09/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175276648 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29,075.00 | 06/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca | No dispute reported | 06/30/2026 | 1175335169 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,926.00 | 06/02/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m | No dispute reported | 06/30/2026 | 1175334836 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,518.00 | 06/02/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175335178 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,164.00 | 05/30/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175335323 |
| Principal investigator 1 | Arrow International, Inc. | $1,727.50 | 05/29/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470403 |
| Principal investigator 1 | Arrow International, Inc. | $615.00 | 05/28/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470399 |
| Principal investigator 1 | Arrow International, Inc. | $8,351.13 | 05/28/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470401 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28.00 | 05/23/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175334788 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,349.00 | 05/23/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175335035 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,459.00 | 05/22/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175335232 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,757.00 | 05/19/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175335279 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,920.00 | 05/12/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175335073 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,009.00 | 05/08/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175335334 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,707.40 | 05/07/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176634132 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $60.00 | 05/07/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176634136 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36,527.00 | 04/28/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175334812 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,188.00 | 04/25/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175334747 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,112.00 | 04/24/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175275726 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,754.00 | 04/24/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175334957 |
| Principal investigator 1 | Janssen Research & Development, LLC | $400.00 | 04/16/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175276308 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,451.60 | 04/09/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632584 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $500.00 | 04/09/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632587 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,451.60 | 04/09/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632592 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,273.00 | 04/07/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175334872 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36,141.00 | 04/07/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175334914 |
| Principal investigator 1 | Teleflex Medical Incorporated | $1,322.50 | 03/31/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470532 |
| Principal investigator 1 | Janssen Research & Development, LLC | $837.00 | 03/27/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175335025 |
| Principal investigator 1 | Janssen Research & Development, LLC | $986.00 | 03/27/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175335042 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,104.00 | 03/24/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175275711 |
| Principal investigator 1 | Janssen Research & Development, LLC | $652.00 | 03/24/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175276802 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,220.00 | 03/21/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175334966 |
| Principal investigator 1 | Janssen Research & Development, LLC | $763.00 | 03/18/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175291900 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,075.00 | 03/17/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175291892 |
| Principal investigator 1 | Calyxo, Inc. | $2,500.00 | 03/14/2025 | Non-covered Recipient Entity Urology Austin, PLLC | ASPIRE | No dispute reported | 06/30/2026 | 1245038295 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,464.00 | 03/14/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175334983 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,370.00 | 03/13/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175335241 |
| Principal investigator 1 | Janssen Research & Development, LLC | $400.00 | 03/10/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175334928 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,413.00 | 03/10/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175335049 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,165.00 | 03/10/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175335195 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,774.00 | 03/10/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175335224 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28,786.00 | 03/10/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175335293 |
| Principal investigator 1 | Janssen Research & Development, LLC | $400.00 | 03/03/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175276322 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,164.00 | 03/03/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175334865 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,404.00 | 02/28/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175335088 |
| Principal investigator 1 | Teleflex LLC | $20,300.00 | 02/28/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | RANDOMIZED TRIAL OF BARRIGEL TO INCREASE DISTANCE BETWEEN THE RECTUM AND PROSTATE BED TO DECREASE RECTAL DOSE IN PATIENTS RECEIVING MODERATELY HYPOFRACTIONATED RADIATION THERAPY WHO HAVE HAD RECURRENCE OF PROSTATE CANCER AFTER PROSTATECTOMY | No dispute reported | 06/30/2026 | 1242432080 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,187.00 | 02/21/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175276152 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,159.00 | 02/14/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175334805 |
| Principal investigator 1 | Janssen Research & Development, LLC | $57,702.00 | 02/10/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175335263 |
| Principal investigator 1 | Teleflex Medical Incorporated | $135.00 | 02/10/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470530 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,914.00 | 02/03/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175334842 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,035.00 | 02/03/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175335016 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $236,229.33 | 01/29/2025 | Non-covered Recipient Entity UROLOGY AUSTIN CORPORATE | a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco | No dispute reported | 06/30/2026 | 1185539483 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,325.00 | 01/28/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175275481 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,986.00 | 01/27/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175335153 |
| Principal investigator 1 | Janssen Research & Development, LLC | $849.00 | 01/24/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175335135 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,525.00 | 01/24/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175335316 |
| Principal investigator 1 | Janssen Research & Development, LLC | $326.00 | 01/22/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175275497 |
| Principal investigator 1 | Janssen Research & Development, LLC | $772.00 | 01/22/2025 | Non-covered Recipient Entity Uro Austin Pllc | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175276495 |
| Principal investigator 1 | Teleflex Medical Incorporated | $985.00 | 01/07/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470526 |
| Principal investigator 1 | Teleflex Medical Incorporated | $975.00 | 01/07/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470528 |
| Principal investigator 1 | Arrow International, Inc. | $1,052.50 | 01/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470355 |
| Principal investigator 1 | Teleflex Medical Incorporated | $985.00 | 01/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470506 |
| Principal investigator 1 | Teleflex Medical Incorporated | $4,265.00 | 01/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470508 |
| Principal investigator 1 | Teleflex Medical Incorporated | $615.00 | 01/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470510 |
| Principal investigator 1 | Teleflex Medical Incorporated | $29.70 | 01/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470512 |
| Principal investigator 1 | Teleflex Medical Incorporated | $135.00 | 01/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470514 |
| Principal investigator 1 | Teleflex Medical Incorporated | $5,373.66 | 01/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470516 |
| Principal investigator 1 | Teleflex Medical Incorporated | $1,997.50 | 01/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470518 |
| Principal investigator 1 | Teleflex Medical Incorporated | $2,105.00 | 01/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470520 |
| Principal investigator 1 | Teleflex Medical Incorporated | $1,120.00 | 01/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470522 |
| Principal investigator 1 | Teleflex Medical Incorporated | $1,930.00 | 01/06/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | INVESTIGATING MEDICATION VERSUS PROSTATIC URETHRAL LIFT:ASSESSMENT AND COMPARISON OF THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA | No dispute reported | 06/30/2026 | 1242470524 |
| Principal investigator 1 | Janssen Research & Development, LLC | $47,115.00 | 01/02/2025 | Non-covered Recipient Entity UROLOGY AUSTIN PLLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175335286 |